SYMJEPI
Anaphylaxis
ApprovedMarketed
Key Facts
About Assertio Holdings
Assertio Holdings is a NASDAQ-listed commercial biotech focused on acquiring and maximizing established pharmaceutical products in neurology, pain management, and hospital care. Its strategy centers on a lean commercial model, targeting non-promoted or under-valued brands for strategic marketing and lifecycle extensions. Recent years have seen significant corporate transformation, including portfolio divestitures and a name change, to sharpen focus on its core therapeutic areas and return to profitability.
View full company profileTherapeutic Areas
Other Anaphylaxis Drugs
| Drug | Company | Phase |
|---|---|---|
| Epinephrine/Adrenaline Alginate Film | Klaria | Pre-clinical/Development |
| Nasefrin | Noveeda | Preclinical |
| Epinephrine Auto-Injector | Viatris | Filed |